For example, if a trial sought to enroll patients with ≥ 35% mortality risk, enrolling IL8-positive patients would result in a strategy equivalent to 25 fewer survivors exposed per 100 patients enrolled, whereas enrolling septic shock patients would result in 19 fewer survivors exposed, compared to enrolling all sepsis patients (Fig. 2b, Additional file 2: Table S7). This evidence concerns the gene CXCL8 and Sepsis.